Shorted
Amplia Therapeutics logo
ATX

Amplia Therapeutics

Pharmaceuticals, Biotechnology & Life Sciences

Amplia Therapeutics Limited focuses on developing therapies targeting focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. The company is positioned within the biotechnology sector, leveraging advanced scientific research to develop clinical candidates aimed at unmet medical needs, potentially offering transformative therapies in oncology and fibrotic diseases.

Short position

short percentage0.01%
reported shorts30.1K
shares on issue513.312M

Amplia Therapeutics (ASX:ATX) has 0.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 30,144 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.23% in November 2024. ATX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Amplia Therapeutics (ATX) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
1 Sept

Amplia Therapeutics (ASX:ATX) Cash Runway and Growth Spending Explained

Highlights Amplia Therapeutics has a sizeable cash reserve and no debt, giving its clinical-stage business a relatively extended funding runway. Higher spending on research and development has lifted cash usage as the company advances its therapeutic programmes. The biotechnology group sits within the broader ASX Healthcare Stocks segment, where funding and development progress remain key themes. The Australian stock market continues to track a mix of global economic signals, commodity m...

Continue reading
Kalkine
Neutral
23 Mar

Is Amplia Therapeutics (ASX:ATX) Advancing Cancer Trial Progress?

Highlights • Amplia reports key clinical milestone in pancreatic cancer program. • Narmafotinib responses contribute to ongoing trial development. • Clinical progress supports broader oncology research framework. Amplia Therapeutics advances pancreatic cancer research through clinical trial progress, highlighting healthcare sector activity within the ASX All Ordinaries framework. The biotechnology and healthcare sector plays a significant role in advancing medical research, drug ...

Continue reading